Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1121-1130 of 1,467) with videos related to

Pageof 147
Sort By:
Arthritis and Rheumatism|March 29, 2002
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerinKurt Redlich, Silvia Hayer, Andrea Maier, et al.
Arthritis Research & Therapy|September 6, 2017
Opportunities and challenges in rheumatology research in Central EuropeZoltán Szekanecz, Branimir Anic, Gábor Héjj, et al.
The Lancet. Rheumatology|January 26, 2024
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysisMark C Genovese, Josef S Smolen, Tsutomu Takeuchi, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic ArthritisSarah M Yazji, Philip S Helliwell, Andra Balanescu, et al.
Arthritis and Rheumatism|March 7, 2001
Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alphaK Redlich, H P Kiener, G Schett, et al.
RMD Open|November 30, 2018
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD studyVibeke Norvang, Joseph Sexton, Eirik K Kristianslund, et al.
The Journal of Rheumatology|March 15, 2026
Further validation of a questionnaire to assess flare in psoriatic arthritis: determination of cut-off and longitudinal changePhilip S Helliwell, Juan D Cañete, Laura C Coates, et al.
Annals of the Rheumatic Diseases|February 14, 2014
The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'Lilian H D van Tuyl, Sarah Hewlett, Martina Sadlonova, et al.
Arthritis and Rheumatism|February 16, 2010
Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritisStephan Blüml, Nikolaus B Binder, Birgit Niederreiter, et al.
Seminars in Arthritis and Rheumatism|April 10, 2016
Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trialDaniel H Solomon, Sara B Lee, Agnes Zak, et al.
Pageof 147

Showing results (1121-1130 of 1,467) with videos related to

Sort By:
Pageof 147
Arthritis and Rheumatism|March 29, 2002
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerinKurt Redlich, Silvia Hayer, Andrea Maier, et al.
Arthritis Research & Therapy|September 6, 2017
Opportunities and challenges in rheumatology research in Central EuropeZoltán Szekanecz, Branimir Anic, Gábor Héjj, et al.
The Lancet. Rheumatology|January 26, 2024
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysisMark C Genovese, Josef S Smolen, Tsutomu Takeuchi, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic ArthritisSarah M Yazji, Philip S Helliwell, Andra Balanescu, et al.
Arthritis and Rheumatism|March 7, 2001
Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alphaK Redlich, H P Kiener, G Schett, et al.
RMD Open|November 30, 2018
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD studyVibeke Norvang, Joseph Sexton, Eirik K Kristianslund, et al.
The Journal of Rheumatology|March 15, 2026
Further validation of a questionnaire to assess flare in psoriatic arthritis: determination of cut-off and longitudinal changePhilip S Helliwell, Juan D Cañete, Laura C Coates, et al.
Annals of the Rheumatic Diseases|February 14, 2014
The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'Lilian H D van Tuyl, Sarah Hewlett, Martina Sadlonova, et al.
Arthritis and Rheumatism|February 16, 2010
Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritisStephan Blüml, Nikolaus B Binder, Birgit Niederreiter, et al.
Seminars in Arthritis and Rheumatism|April 10, 2016
Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trialDaniel H Solomon, Sara B Lee, Agnes Zak, et al.
Pageof 147